RxDoctor Payments Data

Valentine Chikwendu, MD

Cardiovascular Disease · Minot, NDNPI 1356439798

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,536 of the $2,784 with a category attached, or 91.1%. Abbott accounts for 95.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $2,693 and has fallen 98.7% since, to $35 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in ND, where the typical reported total is $2,784.

$2,784in general payments, 2019–2025

Across 14 payments — averaging $198.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Johnson & Johnson$44
  • Atricure, Inc.$35
  • Itamar Medical Inc$25
  • GE HealthCare$14
  • Angiodynamics, Inc.$11

What the payments were for

  • Travel & lodging$2,53691%
  • Food & beverage$2489%

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,784 in reported general payments places this provider in the 50th percentile of 35 cardiovascular disease providers in North Dakota.

See all cardiovascular disease providers in North Dakota

Medicare billing

Part B allowed, 2024
$212,488
Medicare patients
2,039
Services billed
4,341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban347$322,652
XareltoRivaroxaban57$64,335
JardianceEmpagliflozin58$46,905
TrulicityDulaglutide38$40,664
BrilintaTicagrelor35$22,685
EntrestoSacubitril/Valsartan11$22,417
Repatha SyringeEvolocumab25$17,887
OzempicSemaglutide14$11,902
Atorvastatin Calcium704$6,726
Metoprolol Succinate431$6,581
Midodrine Hcl121$6,383
Diltiazem 24hr Er (Cd)Diltiazem Hcl115$5,505
Nitroglycerin PatchNitroglycerin123$4,732
ClopidogrelClopidogrel Bisulfate392$4,628
Potassium Chloride195$3,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$44$64,33557 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 35 cardiovascular disease providers in North Dakota.

Other cardiovascular disease in Minot

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →